Intensity Therapeutics Inc INTS announced that safety, tolerability, efficacy, and immune activation data from its Phase 2 INVINCIBLE trial of INT230-6 in patients with early-stage breast cancer without chemotherapy was presented during the 2023 San Antonio Breast Cancer Symposium.
The INVINCIBLE Phase 2 trial of INT230-6 demonstrated a high order of necrosis (death of tumor tissue) in presurgical breast cancer tumors in the period from diagnosis to surgery, with some patients in the Phase 2 study experiencing greater than 95% necrosis of the tumor.
A functional pathway enrichment analysis was conducted and confirmed positive changes in T-cell activation, lymphocyte activation, and inflammatory response.
Further, INT230-6 treated patients experienced differential gene expression with increased median clonal diversity compared to baseline and significant changes in the immune cell composition, including CD4 T-cell and NK cells.
Data show that INT230-6 has a favorable safety profile and is well tolerated. Over 95% of treatment-emergent adverse events were low-grade 1 or 2, primarily localized pain, fatigue, and nausea.
Price Action: INTS shares are up 150% at $10.00 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
